Kidswell Bio Corporation (4584.T)
JPY 102.0
(-7.27%)
JPY 102.0
(-7.27%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.38 Billion JPY | -129.18% |
| 2022 | -620.45 Million JPY | 5.97% |
| 2021 | -531.89 Million JPY | 35.72% |
| 2020 | -982.99 Million JPY | 16.11% |
| 2019 | -7.3 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -158.71 Million JPY | 75.25% |
| 2023 Q2 | -300.25 Million JPY | 34.55% |
| 2023 Q1 | -458.71 Million JPY | -1.47% |
| 2023 Q4 | -666.86 Million JPY | -1766.57% |
| 2023 Q3 | 40.01 Million JPY | 113.33% |
| 2023 FY | - JPY | -129.18% |
| 2022 Q3 | -152.24 Million JPY | -408.4% |
| 2022 FY | - JPY | 5.97% |
| 2022 Q4 | -452.08 Million JPY | -196.95% |
| 2022 Q2 | 49.36 Million JPY | 0.0% |
| 2021 FY | - JPY | 35.72% |
| 2020 FY | - JPY | 16.11% |
| 2019 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 244.12% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | -182.879% |
| GNI Group Ltd. | 14.48 Billion JPY | 109.53% |
| Linical Co., Ltd. | 1.24 Billion JPY | 210.711% |
| Trans Genic Inc. | 240.95 Million JPY | 673.069% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | -1.841% |
| Soiken Holdings Inc. | -583.2 Million JPY | -136.764% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | -128.957% |
| AnGes, Inc. | -8.86 Billion JPY | 84.415% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | -7.416% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 81.338% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 1177.865% |
| NanoCarrier Co., Ltd. | -863 Million JPY | -60.002% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | -26.474% |
| CanBas Co., Ltd. | 53.65 Million JPY | 2673.71% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | -78.035% |
| RaQualia Pharma Inc. | -111.8 Million JPY | -1135.07% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | -13.954% |
| PeptiDream Inc. | 7.37 Billion JPY | 118.72% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 28.443% |
| Ribomic Inc. | -1.01 Billion JPY | -36.374% |
| SanBio Company Limited | -4.52 Billion JPY | 69.485% |
| Healios K.K. | -3 Billion JPY | 54.08% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | -18.445% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 0.879% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 1.511% |
| StemRIM | -2.03 Billion JPY | 32.046% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 205.693% |
| FunPep Company Limited | -952 Million JPY | -45.044% |
| Kringle Pharma, Inc. | -888.76 Million JPY | -55.365% |
| Stella Pharma Corporation | -723.85 Million JPY | -90.76% |
| TMS Co., Ltd. | -937 Million JPY | -47.366% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -78.081% |
| Cuorips Inc. | -518 Million JPY | -166.568% |
| K Pharma,Inc. | 366.05 Million JPY | 477.214% |
| Takara Bio Inc. | 8.02 Billion JPY | 117.209% |
| ReproCELL Incorporated | 8.24 Million JPY | 16847.374% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | 1670.221% |
| StemCell Institute Inc. | 534.35 Million JPY | 358.409% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 664.029% |
| CellSeed Inc. | -836.51 Million JPY | -65.068% |